KGaA, Weinheim.Phase-stable CsSnx Pb1-x I3 perovskite quantum dots (QDs) hold great promise for optoelectronic applications owing to their strong response in the near-infrared region. Unfortunately, optimal utilization of their potential is limited by the severe photoluminescence (PL) quenching, leading to extremely low quantum yields (QYs) of approximately 0.3 %. The ultra-low sodium (Na) doping presented herein is found to be effective in improving PL QYs of these alloyed QDs without alerting their favourable electronic structure. X-ray photoelectron spectroscopy (XPS) studies suggest the formation of a stronger chemical interaction between I- and Sn2+ ions upon Na doping, which potentially helps to stabilize Sn2+ and suppresses the formation of I vacancy defects. The optimized PL QY of the Na-doped QDs reaches up to around 28 %, almost two orders of magnitude enhancement compared with the pristine one. © 2020 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim.Endeavor to discover biorational natural products-based insecticides, two series (30) of novel 9 S -acyloxy derivatives of quinidine and dihydroquinidine were prepared and assessed for their insecticidal activity against Mythimna separata in vivo by the leaf-dipping method at 1 mg/mL. Among all the compounds, especially derivatives 3k , 3m , 3u , and 4k exhibited the best insecticidal activity with final mortality rates of 71.4%, 75.0%, 71.4%, and 75.0%, respectively. Relatively speaking, 9-hydroxyl group is well tolerated, and the results showed that after modification of hydroxyl group with acyloxy, the insecticidal activity was significantly increased; the configuration of C8/9 position is important for insecticidal activity, and 9 S -configuration is optimal; modification of out-ring double-bond is acceptable, and hydrogenation of double-bond enhances insecticidal activity. These preliminary results will pave the way for further modification of quinidine in the development of potential new insecticides. © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.The present work was aimed to evaluate the protective effects of alpha-tocopherol (α-toco) and/or Lactobacillus plantarum (LCB) against testicular atrophy induced by mercuric chloride (MCH). Rats were injected with 5 mg/kg MCH for 5 days consecutively, then treated with 100 mg/kg α-toco and 6 × 1010 CFU 1.8701/kg LCB alone or together for 3 weeks. The MCH elevated serum TNF-α, IL- 6, caspase-3, and testicular malondialdehyde. However, serum testosterone, dehydroepiandrosterone, testicular messenger RNA of a steroidogenic acute regulatory protein, 17-β-hydroxysteroid dehydrogenase, 3β-hydroxysteroid dehydrogenase, glutathione level, and superoxide dismutase activity were decreased. Protein expression of Nrf2 was downregulated whereas that of Bax and DNA fragmentation was upregulated in the testicular tissues. Treatment with α-toco and LCB ameliorated the deviated biochemical parameters and improved tissue injury. It was concluded that the combination of LCB and α-toco achieved promising results in the amelioration of MCH-induced testicular atrophy. Nrf2, Bax expressions, and DNA fragmentation are involved in the testicular atrophy induced by MCH. © 2020 Wiley Periodicals, Inc.Electrocatalytic CO 2 reduction to a single product at high current densities and efficiencies remains a challenge. However, the conventional electrode preparation methods, such as drop-casting, usually suffer from low intrinsic activity. Herein, we report a synthesis strategy for preparing heterogeneous electrocatalyst composed of 3D hierarchical Cu dendrites that derived from the in-situ electrosynthesized hollow Cu-metal organic framework (MOF), which took only 5min for the preparation of the Cu-MOF film. The synthesis strategy preferentially exposes increasing active sites, which favours for the reduction of CO 2 to formate. The current density could be as high as 102.1 mA cm -2 with a selectivity of 98.3% in ionic-liquid based electrolyte and a commonly used H-type cell. © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.In the development of enzymatic biosensors, the use of electrochromic mediators has been accepted and widely used during decades. The main drawback of this type of enzymatic substrates is the difficult recovery of the initial redox state of the molecule, which can be done electrochemically or by antioxidants addition, complicating the initially simple structure of the biosensor. Actually, those strategies are rarely followed; being the single-use biosensor configuration the most extended for this detection mechanisms. Alternatively, we propose the first reported use of a diacid dithienylethene 1,2-bis(5-carboxy-2-methylthien-3-yl)cyclopentene (DTE) photoelectrochromic compound as a substrate of the horseradish peroxidase (HRP). The photoisomerization between the open (DTEo) and closed (DTEc) forms of the molecule and the respective shift in the redox potential allowed the light-induced enzymatic detection of glucose in the glucose oxidase (GOx) - HRP cascade system. This fast and easy control over the enzymatic substrate availability by light pulses permits a gradually consumption and the light-regeneration of the biosensor for a number of cycles. https://www.selleckchem.com/products/Etopophos.html We consider the presented results transcendent in the development of all-photonic, reusable and light-controlled photonic biosensing systems. © 2020 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.LESSONS LEARNED Results of the KEYNOTE-032 study showed that the safety and pharmacokinetic profiles of pembrolizumab in Chinese patients were comparable with those observed in international studies, and antitumor activity was encouraging. These data support further evaluation of pembrolizumab to improve clinical outcomes in Chinese patients with advanced non-small cell lung cancer. BACKGROUND The KEYNOTE-032 study evaluated pembrolizumab pharmacokinetics and clinical outcomes in Chinese patients with locally advanced and/or metastatic non-small-cell lung cancer (NSCLC) and prior treatment failure and/or ineligibility for standard therapy. METHODS Patients were randomized 111 to pembrolizumab 2 mg/kg, 10 mg/kg, or 200 mg every 3 weeks (up to 35 cycles). Safety and pharmacokinetics were primary endpoints; antitumor activity was a secondary endpoint. RESULTS A total of 42 of 44 randomized patients received pembrolizumab treatment (2 mg/kg, n = 14; 10 mg/kg, n = 13; 200 mg, n = 15). Treatment-related adverse events (AEs) occurred in 29 of 42 (69%) patients (grade 3-4, 4/42 [10%]); 5 (12%) had immune-mediated AEs and infusion reactions.